TuHURA Biosciences (HURA) - Long-Term Debt to Capital

The confirmed price history on the (separate_debt_long_eq) chart demonstrates the performance of TuHURA Biosciences, Inc. (HURA), a biotech developer of personalized immune therapies for oncology centers, where the metric stands at 0.21. Market capitalization relies on patents for overcoming tumor resistance, rendering the asset speculative until the conclusion of R&D. The vaccine network being created by TuHURA Biosciences, Inc. in conjunction with baseline therapy promises to become a key link in modern medicine.

This indicator measures the proportion of liabilities with a maturity exceeding one year relative to equity, determining the business's debt load. By analyzing long-term credit leverage, an investor can assess the ability of TuHURA Biosciences, Inc. (HURA) to finance costly ultra-cold vaccine logistics without excessive borrowing, which is critical for maintaining financial stability while scaling supply chains.